Incyte Corporation
General ticker "INCY" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $14.5B (TTM average)
Incyte Corporation follows the US Stock Market performance with the rate: 60.7%.
Estimated limits based on current volatility of 1.3%: low 96.88$, high 99.45$
Factors to consider:
- Company included in S&P500 list
- Total employees count: 2617 (+3.7%) as of 2024
- US accounted for 94.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Supply chain disruptions, Labor/talent shortage/retention, Strategic risks and growth management, Market disruptions, Operational and conduct risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [79.57$, 120.06$]
- 2026-12-31 to 2027-12-31 estimated range: [81.22$, 122.89$]
Financial Metrics affecting the INCY estimates:
- Positive: with PPE of 14.7 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 26.12 > 18.38
- Positive: 6.64 < Operating cash flow per share per price, % of 7.26
- Positive: Return on assets ratio (scaled to [-100,100]) of 15.61 > 6.11
- Positive: Investing cash flow per share per price, % of -0.53 > -0.63
- Positive: Shareholder equity ratio, % of 74.27 > 64.29
- Positive: Inventory ratio change, % of 0.56 <= 0.80
Short-term INCY quotes
Long-term INCY plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $3,695.65MM | $4,241.22MM | $5,141.24MM |
| Operating Expenses | $3,075.12MM | $4,179.85MM | $3,798.49MM |
| Operating Income | $620.52MM | $61.37MM | $1,342.75MM |
| Non-Operating Income | $213.69MM | $255.26MM | $321.70MM |
| Interest Expense | $2.55MM | $2.28MM | $2.43MM |
| R&D Expense | $1,627.59MM | $2,606.85MM | $1,983.57MM |
| Income(Loss) | $834.22MM | $316.63MM | $1,664.45MM |
| Taxes | $236.62MM | $284.01MM | $377.80MM |
| Profit(Loss)* | $597.60MM | $32.62MM | $1,286.65MM |
| Stockholders Equity | $5,189.84MM | $3,447.63MM | $5,167.48MM |
| Inventory | $62.97MM | $58.87MM | $101.06MM |
| Assets | $6,782.11MM | $5,444.32MM | $6,957.97MM |
| Operating Cash Flow | $496.49MM | $335.34MM | $1,413.50MM |
| Capital expenditure | $47.49MM | $86.26MM | $58.87MM |
| Investing Cash Flow | $-207.68MM | $157.52MM | $-102.61MM |
| Financing Cash Flow | $-20.03MM | $-2,021.55MM | $101.04MM |
| Earnings Per Share** | $2.67 | $0.16 | $6.59 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.